CRVSCorvus PharmaceuticalsCRVS info
$5.48info-0.36%24h
Global rank15425
Market cap$268.73M
Change 7d-
YTD Performance216.76%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Corvus Pharmaceuticals (CRVS) Stock Overview

    Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

    CRVS Stock Information

    Symbol
    CRVS
    Address
    863 Mitten RoadBurlingame, CA 94010United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.corvuspharma.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 900 4520

    Corvus Pharmaceuticals (CRVS) Price Chart

    -
    Value:-

    Corvus Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $5.48
    N/A
    Market Cap
    $268.73M
    N/A
    Shares Outstanding
    49.04M
    N/A
    Employees
    29.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org